Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127986121 | 12798612 | 1 | I | 20110325 | 20110611 | 20160930 | 20160930 | EXP | US-ROCHE-784343 | ROCHE | 62.00 | YR | F | Y | 71.60000 | KG | 20160930 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127986121 | 12798612 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | OVER 30-90 MINUTES ON DAY 1. DATE OF LAST DOSE PRIOR TO SAE: 23 MARCH 2011, DOSE OF BEVACIZUMAB (108 | N | 125085 | 15 | MG/KG | |||||||
| 127986121 | 12798612 | 2 | SS | PACLITAXEL. | PACLITAXEL | 1 | Intravenous (not otherwise specified) | OVER 3 HRS ON DAY 1X 6 CYCLES. DATE OF LAST DOSE PRIOR TO SAE 23 MARCH 2011 | N | 0 | 175 | MG/M**2 | |||||||
| 127986121 | 12798612 | 3 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | AUC 6 OVER 30 MINUTES ON DAY 1 | N | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127986121 | 12798612 | 1 | Endometrial adenocarcinoma |
| 127986121 | 12798612 | 2 | Endometrial adenocarcinoma |
| 127986121 | 12798612 | 3 | Endometrial adenocarcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127986121 | 12798612 | LT |
| 127986121 | 12798612 | OT |
| 127986121 | 12798612 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127986121 | 12798612 | Abdominal pain | |
| 127986121 | 12798612 | Acidosis | |
| 127986121 | 12798612 | Anaemia | |
| 127986121 | 12798612 | Blood alkaline phosphatase increased | |
| 127986121 | 12798612 | Cough | |
| 127986121 | 12798612 | Dehydration | |
| 127986121 | 12798612 | Diarrhoea | |
| 127986121 | 12798612 | Dyspnoea | |
| 127986121 | 12798612 | Fatigue | |
| 127986121 | 12798612 | Haemoglobin decreased | |
| 127986121 | 12798612 | Hyperglycaemia | |
| 127986121 | 12798612 | Hypoalbuminaemia | |
| 127986121 | 12798612 | Hypocalcaemia | |
| 127986121 | 12798612 | Hypokalaemia | |
| 127986121 | 12798612 | Hyponatraemia | |
| 127986121 | 12798612 | Large intestine perforation | |
| 127986121 | 12798612 | Lymphocyte count decreased | |
| 127986121 | 12798612 | Lymphopenia | |
| 127986121 | 12798612 | Neutrophil count decreased | |
| 127986121 | 12798612 | Rectal haemorrhage | |
| 127986121 | 12798612 | Sepsis | |
| 127986121 | 12798612 | Stomatitis | |
| 127986121 | 12798612 | Urinary tract infection | |
| 127986121 | 12798612 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127986121 | 12798612 | 2 | 20110323 | 0 | ||
| 127986121 | 12798612 | 3 | 20110323 | 0 |